Compare VELO & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VELO | STIM |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 102.9M | 105.5M |
| IPO Year | N/A | 2018 |
| Metric | VELO | STIM |
|---|---|---|
| Price | $17.83 | $1.79 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $18.00 | $7.00 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 02-26-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $49,158,000.00 | ★ $129,873,000.00 |
| Revenue This Year | $30.60 | $101.67 |
| Revenue Next Year | $57.71 | $10.87 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 59.44 | ★ 78.61 |
| 52 Week Low | $1.43 | $1.25 |
| 52 Week High | $23.84 | $5.92 |
| Indicator | VELO | STIM |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.75 |
| Support Level | N/A | $1.73 |
| Resistance Level | N/A | $2.13 |
| Average True Range (ATR) | 0.00 | 0.18 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 0.00 | 60.69 |
Velo3D Inc provides additive manufacturing (AM), also referred to as three-dimensional printing (3D printing), to deliver breakthroughs in performance, cost, and time in the production of high-value metal parts. The Velo3D intelligent metal additive manufacturing solution is comprised of the Velo3D Flow intelligent print preparation software, the Sapphire production system, and Velo3D Assure, real-time quality assurance software. Its complete manufacturing solution enables clients to build the parts needed, speed their development, and reduce their product costs.
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.